Genus plc (LON:GNS – Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 2,573.74 and traded as high as GBX 3,065. Genus shares last traded at GBX 3,060, with a volume of 182,667 shares.
Analysts Set New Price Targets
Several research firms have recently commented on GNS. Shore Capital reissued a “buy” rating and set a GBX 3,000 target price on shares of Genus in a research report on Friday, January 16th. Deutsche Bank Aktiengesellschaft boosted their price objective on Genus from GBX 3,100 to GBX 3,300 and gave the stock a “buy” rating in a report on Friday, January 16th. Finally, Berenberg Bank raised their target price on Genus from GBX 3,050 to GBX 3,250 and gave the company a “buy” rating in a report on Friday, January 16th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of GBX 3,183.33.
Genus Stock Up 0.5%
About Genus
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
See Also
- Five stocks we like better than Genus
- Your Bank Account Is No Longer Safe
- Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It
- 1 Hour Once A Day
- What a Former CIA Agent Knows About the Coming Collapse
- They just tried to kill gold
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
